Shenda Gu

3.3k total citations · 1 hit paper
17 papers, 2.2k citations indexed

About

Shenda Gu is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Shenda Gu has authored 17 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 6 papers in Oncology and 4 papers in Biomaterials. Recurrent topics in Shenda Gu's work include RNA Interference and Gene Delivery (6 papers), Advanced biosensing and bioanalysis techniques (6 papers) and Nanoparticle-Based Drug Delivery (4 papers). Shenda Gu is often cited by papers focused on RNA Interference and Gene Delivery (6 papers), Advanced biosensing and bioanalysis techniques (6 papers) and Nanoparticle-Based Drug Delivery (4 papers). Shenda Gu collaborates with scholars based in United States, Australia and Switzerland. Shenda Gu's co-authors include Joe W. Gray, Eric A. Collisson, Paul T. Spellman, Anguraj Sadanandam, Andrew H. Ko, J. Cooc, William J. Gibb, Douglas Hanahan, Morgan Truitt and Grace Kim and has published in prestigious journals such as Nature Medicine, PLoS ONE and Biomaterials.

In The Last Decade

Shenda Gu

16 papers receiving 2.2k citations

Hit Papers

Subtypes of pancreatic ductal adenocarcinoma and their di... 2011 2026 2016 2021 2011 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy
    2011 1.2k citations Eric A. Collisson, Anguraj Sadanandam et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shenda Gu United States 13 1.3k 1.1k 764 255 236 17 2.2k
Kristopher K. Frese United Kingdom 13 1.2k 0.9× 646 0.6× 460 0.6× 150 0.6× 200 0.8× 13 1.8k
Amy Chang United States 13 1.4k 1.1× 738 0.7× 446 0.6× 230 0.9× 421 1.8× 28 2.3k
Sérgia Velho Portugal 21 811 0.6× 830 0.8× 307 0.4× 363 1.4× 212 0.9× 36 1.8k
Pedro P. López‐Casas Spain 25 978 0.8× 702 0.6× 540 0.7× 340 1.3× 144 0.6× 52 1.8k
Jianguo Wang China 21 606 0.5× 1.1k 1.0× 496 0.6× 204 0.8× 311 1.3× 49 2.0k
Chad V. Pecot United States 26 865 0.7× 1.8k 1.6× 1.1k 1.4× 343 1.3× 415 1.8× 59 2.9k
Alberta Locatelli Italy 17 846 0.7× 1.1k 1.0× 648 0.8× 201 0.8× 161 0.7× 31 2.0k
Serena Marchiò Italy 25 494 0.4× 990 0.9× 273 0.4× 166 0.7× 245 1.0× 45 1.9k
Jacson Shen United States 28 689 0.5× 981 0.9× 523 0.7× 617 2.4× 134 0.6× 52 2.0k
Giovanni Esposito Italy 30 768 0.6× 1.1k 1.0× 637 0.8× 196 0.8× 68 0.3× 65 2.1k

Countries citing papers authored by Shenda Gu

Since Specialization
Citations

This map shows the geographic impact of Shenda Gu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenda Gu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenda Gu more than expected).

Fields of papers citing papers by Shenda Gu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shenda Gu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenda Gu. The network helps show where Shenda Gu may publish in the future.

Co-authorship network of co-authors of Shenda Gu

This figure shows the co-authorship network connecting the top 25 collaborators of Shenda Gu. A scholar is included among the top collaborators of Shenda Gu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shenda Gu. Shenda Gu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
2.
Reda, Moataz, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2019). PLK1 and EGFR targeted nanoparticle as a radiation sensitizer for non-small cell lung cancer. Cancer Letters. 467. 9–18. 56 indexed citations
3.
Ngamcherdtrakul, Worapol, Thanapon Sangvanich, Shaun M. Goodyear, et al.. (2019). Lanthanide-Loaded Nanoparticles as Potential Fluorescent and Mass Probes for High-Content Protein Analysis. Bioengineering. 6(1). 23–23. 12 indexed citations
4.
Gu, Shenda, Worapol Ngamcherdtrakul, Moataz Reda, et al.. (2018). Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS ONE. 13(6). e0198141–e0198141. 19 indexed citations
5.
Ngamcherdtrakul, Worapol, Thanapon Sangvanich, Moataz Reda, et al.. (2018). Lyophilization and stability of antibody-conjugated mesoporous silica nanoparticle with cationic polymer and PEG for siRNA delivery. International Journal of Nanomedicine. Volume 13. 4015–4027. 55 indexed citations
6.
Morry, Jingga, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2017). Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform. Molecular Cancer Therapeutics. 16(4). 763–772. 51 indexed citations
7.
Ngamcherdtrakul, Worapol, David J. Castro, Shenda Gu, et al.. (2016). Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treatment Reviews. 45. 19–29. 23 indexed citations
8.
Gu, Shenda, Zhi Hu, Worapol Ngamcherdtrakul, et al.. (2016). Therapeutic siRNA for drug-resistant HER2-positive breast cancer. Oncotarget. 7(12). 14727–14741. 38 indexed citations
9.
Morry, Jingga, Worapol Ngamcherdtrakul, Shenda Gu, et al.. (2015). Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials. 66. 41–52. 56 indexed citations
10.
Ngamcherdtrakul, Worapol, Jingga Morry, Shenda Gu, et al.. (2015). Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer. Advanced Functional Materials. 25(18). 2646–2659. 167 indexed citations
11.
Ngamcherdtrakul, Worapol, Jingga Morry, Shenda Gu, et al.. (2015). Cancer Nanomedicine: Cationic Polymer Modified Mesoporous Silica Nanoparticles for Targeted siRNA Delivery to HER2+ Breast Cancer (Adv. Funct. Mater. 18/2015). Advanced Functional Materials. 25(18). 2629–2629. 1 indexed citations
12.
Draz, Mohamed S., Binbin Fang, Pengfei Zhang, et al.. (2014). Nanoparticle-Mediated Systemic Delivery of siRNA for Treatment of Cancers and Viral Infections. Theranostics. 4(9). 872–892. 182 indexed citations
13.
Collisson, Eric A., Christy L. Trejo, Jillian M. Silva, et al.. (2012). A Central Role for RAF→MEK→ERK Signaling in the Genesis of Pancreatic Ductal Adenocarcinoma. Cancer Discovery. 2(8). 685–693. 219 indexed citations
14.
Collisson, Eric A., Anguraj Sadanandam, Peter Olson, et al.. (2011). Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nature Medicine. 17(4). 500–503. 1184 indexed citations breakdown →
15.
Hu, Zhi, Ge Huang, Anguraj Sadanandam, et al.. (2010). The expression level of HJURP has an independent prognostic impact and predicts the sensitivity to radiotherapy in breast cancer. Breast Cancer Research. 12(2). R18–R18. 109 indexed citations
16.
Hu, Zhi, Wen‐Lin Kuo, Debopriya Das, et al.. (2009). Abstract #5572: Small molecular inhibitor of centromere-associated protein E (CENP-E), GSK923295A inhibits cell growth in breast cancer cells. Cancer Research. 69. 5572–5572. 1 indexed citations
17.
Hu, Zhanying, Jian‐Hua Mao, Guanhao Huang, et al.. (2009). A Systems Analysis of Mitotic Apparatus Inhibitors Defines a Response Network for Breast Cancer.. Cancer Research. 69(24_Supplement). 2020–2020. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kristopher K. Frese Breakdown of academic impact, for papers by Amy Chang Breakdown of academic impact, for papers by Sérgia Velho Breakdown of academic impact, for papers by Pedro P. López‐Casas Breakdown of academic impact, for papers by Jianguo Wang Breakdown of academic impact, for papers by Chad V. Pecot Breakdown of academic impact, for papers by Alberta Locatelli Breakdown of academic impact, for papers by Serena Marchiò Breakdown of academic impact, for papers by Jacson Shen Breakdown of academic impact, for papers by Giovanni Esposito
Rankless by CCL
2026